Study on the application of aptamers in the screening of tumor serum markers_Journal of Biomedical Engineering

Authors：

MA Shuling ,  ZENG Jiayu

College of Life Science, Northwest Normal University, Lanzhou 730070, P.R.China;

Corresponding?author：

Keywords：

aptamer; tumor serum biomarker; tumor diagnosis

DOI：

10.7507/1001-5515.201710026

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

The nucleic acid adapters of tumor serum markers are oligonucleotide molecules with high specificity and high affinity with tumor serum markers obtained by in vitro screening with systematic evolution of ligands by exponential enrichment (SELEX). Researchers take the advantage of the nucleic acid adapter to explore new tumor serum markers that have more diagnostic value for tumor diagnosis. Recently, some achievements have been achieved in the research of liver cancer and stomach cancer. This paper has reviewed nucleic acid adapter and its research in the serum tumor marker screening, and discussed the value of the nucleic acid adapter of serum tumor markers in the diagnosis, as well as current problems existing in the research. This paper is very useful to help people better understand the screening of nucleic acid adapters of tumor serum markers, and to provide help in discovering new tumor serum markers.

Citation： MA Shuling, ZENG Jiayu. Study on the application of aptamers in the screening of tumor serum markers. Journal of Biomedical Engineering, 2018, 35(2): 320-323. doi: 10.7507/1001-5515.201710026 Copy

1.	Fitzmaurice C, Allen C, Barber R M, et al. Global, regional, and National cancer incidence, mortality, years of Life lost, years lived with disability, and Disability-Adjusted life-years for 32 cancer groups, 1990 to 2015 a systematic analysis for the global burden of disease study. JAMA Oncology, 2017, 3(4): 524-548.
2.	Chen Wanqing, Zheng Rongshou, Baade P D, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
3.	李林海. 常見腫瘤標志物的臨床應用及進展. 中華檢驗醫學雜志, 2016, 39(12): 995-998.
4.	張永, 李曉勇, 宋瑜, 等. 優化腫瘤標志物群建立的決策樹模型對肝癌輔助診斷的價值. 鄭州大學學報: 醫學版, 2015, 50(6): 794-797.
5.	Alsalloom A A. An update of biochemical markers of hepatocellular carcinoma. Int J Health Sci (Qassim), 2016, 10(1): 121-136.
6.	Veli C Q, Gulay B, Zehra E, et al. Pathogen detection in complex samples by quartz crystal microbalance sensor coupled to aptamer functionalized core-shell type magnetic separation. Anal Chim Acta, 2015, 853(3): 533-540.
7.	Zhao Bianjun, Wu Ping, Zhang Hui, et al. Designing activatable aptamer probes for simultaneous detection of multiple tumor-related proteins in living cancer cells. Biosens Bioelectron, 2015, 68(2): 763-770.
8.	靳貴曉, 李娟, 楊黃浩. 核酸適體的篩選及其在生物醫學領域的研究進展. 福州大學學報, 2016, 44(6):919-935.
9.	楊歌, 魏強, 趙新穎, 等. 蛋白質的核酸適配體篩選的研究進展. 色譜, 2016, 34(4): 370-381.
10.	曾家豫, 萬波, 馬瑾, 等. 癌胚抗原特異性單克隆抗體(Anti-CEA)核酸適配體的篩選. 南京醫科大學學報: 自然科學版, 2015, 35(6): 782-786.
11.	陳弘煒, 王開宇, 蘭小鵬. 金黃色葡萄球菌毒性休克綜合征毒素1核酸適配體的篩選. 生物技術通訊, 2016, 27(1): 86-89.
12.	Chen Ye, Gao Shegan, Chen Jianmin, et al. Serum CA242, CA199, CA125, CEA, and TSGF are biomarkers for the efficacy and prognosis of cryoablation in pancreatic cancer patients. Cell Biochem Biophys, 2015, 71(3): 1287-1291.
13.	Chen B, Wu G R, Yang W Y, et al. Diagnostic value of HE4 CYFRA21-1 in combination with and TPS for early diagnosis of non-small cell lung cancer. Journal of Practical Medicine, 2016, 22(1): 734-736.
14.	Chen L. Analysis on the value of combined detection of CYFRA21-1, NSE, CEA, CA125 in lung carcinoma. International Journal of Laboratory Medicine, 2016, 37(8): 1057-1059.
15.	Gobin R, Bogard D, Chauvin N, et al. International fusion materials irradiation facility injector acceptance tests at CEA/Saclay: 140 mA/100 keV deuteron beam characterization. Review of Scientific Instruments, 2015, 85(2):02A918.
16.	Coleman C. Early detection and screening for breast cancer. Semin Oncol Nurs, 2017, 33(2): 141-155.
17.	Berezovski M V, Lechmann M, Musheev M U, et al. Aptamer-facilitated biomarker discovery (AptaBiD). J Am Chem Soc, 2008, 130(28): 9137-9143.
18.	陳文學. 肝癌血清核酸適配體的篩選及其鑒定. 南昌: 南昌大學, 2011.
19.	張洪麗. 胃癌血清適配子對胃癌診斷價值的研究. 南昌: 南昌大學, 2015.
20.	葸玉琴, 趙運旺, 李東東, 等. 胃癌血清適配體的篩選及其鑒定. 南京醫科大學學報:自然科學版, 2016, 36(11): 1306-1312.
21.	Mi Jing, Liu Yingmiao, Rabbani Z N, et al. In vivo selection of tumor-targeting RNA motifs. Nat Chem Biol, 2010, 6(1): 22-24.
22.	方念. AFP-L3核酸適配子的篩選鑒定及其對肝細胞癌診斷價值的初步研究. 南昌: 南昌大學, 2008.
23.	萬波. 癌胚抗原特異性單克隆抗體核酸適配體的篩選. 蘭州: 西北師范大學, 2015.
24.	Gold L, Ayers D, Bertino J, et al. Aptamer-Based multiplexed proteomic technology for biomarker discovery. PLoS One, 2010, 5(12): 15004.
25.	Ostroff R M, Bigbee W L, Franklin W, et al. Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer. PLoS One, 2010, 5(12): 15003.

1. Fitzmaurice C, Allen C, Barber R M, et al. Global, regional, and National cancer incidence, mortality, years of Life lost, years lived with disability, and Disability-Adjusted life-years for 32 cancer groups, 1990 to 2015 a systematic analysis for the global burden of disease study. JAMA Oncology, 2017, 3(4): 524-548.
2. Chen Wanqing, Zheng Rongshou, Baade P D, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
3. 李林海. 常見腫瘤標志物的臨床應用及進展. 中華檢驗醫學雜志, 2016, 39(12): 995-998.
4. 張永, 李曉勇, 宋瑜, 等. 優化腫瘤標志物群建立的決策樹模型對肝癌輔助診斷的價值. 鄭州大學學報: 醫學版, 2015, 50(6): 794-797.
5. Alsalloom A A. An update of biochemical markers of hepatocellular carcinoma. Int J Health Sci (Qassim), 2016, 10(1): 121-136.
6. Veli C Q, Gulay B, Zehra E, et al. Pathogen detection in complex samples by quartz crystal microbalance sensor coupled to aptamer functionalized core-shell type magnetic separation. Anal Chim Acta, 2015, 853(3): 533-540.
7. Zhao Bianjun, Wu Ping, Zhang Hui, et al. Designing activatable aptamer probes for simultaneous detection of multiple tumor-related proteins in living cancer cells. Biosens Bioelectron, 2015, 68(2): 763-770.
8. 靳貴曉, 李娟, 楊黃浩. 核酸適體的篩選及其在生物醫學領域的研究進展. 福州大學學報, 2016, 44(6):919-935.
9. 楊歌, 魏強, 趙新穎, 等. 蛋白質的核酸適配體篩選的研究進展. 色譜, 2016, 34(4): 370-381.
10. 曾家豫, 萬波, 馬瑾, 等. 癌胚抗原特異性單克隆抗體(Anti-CEA)核酸適配體的篩選. 南京醫科大學學報: 自然科學版, 2015, 35(6): 782-786.
11. 陳弘煒, 王開宇, 蘭小鵬. 金黃色葡萄球菌毒性休克綜合征毒素1核酸適配體的篩選. 生物技術通訊, 2016, 27(1): 86-89.
12. Chen Ye, Gao Shegan, Chen Jianmin, et al. Serum CA242, CA199, CA125, CEA, and TSGF are biomarkers for the efficacy and prognosis of cryoablation in pancreatic cancer patients. Cell Biochem Biophys, 2015, 71(3): 1287-1291.
13. Chen B, Wu G R, Yang W Y, et al. Diagnostic value of HE4 CYFRA21-1 in combination with and TPS for early diagnosis of non-small cell lung cancer. Journal of Practical Medicine, 2016, 22(1): 734-736.
14. Chen L. Analysis on the value of combined detection of CYFRA21-1, NSE, CEA, CA125 in lung carcinoma. International Journal of Laboratory Medicine, 2016, 37(8): 1057-1059.
15. Gobin R, Bogard D, Chauvin N, et al. International fusion materials irradiation facility injector acceptance tests at CEA/Saclay: 140 mA/100 keV deuteron beam characterization. Review of Scientific Instruments, 2015, 85(2):02A918.
16. Coleman C. Early detection and screening for breast cancer. Semin Oncol Nurs, 2017, 33(2): 141-155.
17. Berezovski M V, Lechmann M, Musheev M U, et al. Aptamer-facilitated biomarker discovery (AptaBiD). J Am Chem Soc, 2008, 130(28): 9137-9143.
18. 陳文學. 肝癌血清核酸適配體的篩選及其鑒定. 南昌: 南昌大學, 2011.
19. 張洪麗. 胃癌血清適配子對胃癌診斷價值的研究. 南昌: 南昌大學, 2015.
20. 葸玉琴, 趙運旺, 李東東, 等. 胃癌血清適配體的篩選及其鑒定. 南京醫科大學學報:自然科學版, 2016, 36(11): 1306-1312.
21. Mi Jing, Liu Yingmiao, Rabbani Z N, et al. In vivo selection of tumor-targeting RNA motifs. Nat Chem Biol, 2010, 6(1): 22-24.
22. 方念. AFP-L3核酸適配子的篩選鑒定及其對肝細胞癌診斷價值的初步研究. 南昌: 南昌大學, 2008.
23. 萬波. 癌胚抗原特異性單克隆抗體核酸適配體的篩選. 蘭州: 西北師范大學, 2015.
24. Gold L, Ayers D, Bertino J, et al. Aptamer-Based multiplexed proteomic technology for biomarker discovery. PLoS One, 2010, 5(12): 15004.
25. Ostroff R M, Bigbee W L, Franklin W, et al. Unlocking biomarker discovery: large scale application of aptamer proteomic technology for early detection of lung cancer. PLoS One, 2010, 5(12): 15003.

Previous Article
Recent progress in nanomedicine for hepatocellular carcinoma therapy
Next Article
Smart drug delivery systems based on nanoscale ZnO

Journal of Biomedical Engineering

Study on the application of aptamers in the screening of tumor serum markers

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content